Skip to main content

Dr. Wade B. May, MD

Cardiology (Cardiovascular Disease Physician)

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2007
Medicare patients seen, 2024
3,115

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: Louisiana State University School of Medicine in New Orleans
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Cardiovascular Disease Physician primary
    LA license 200957

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Cardiology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
3,115
Services billed
24,125
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session4,778252
Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session4,460243
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report2,2991,742
Established patient office or other outpatient visit, 30-39 minutes1,567986
Established patient office or other outpatient visit, 20-29 minutes1,3181,141
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function764751
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month61265
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only534399
Injection, regadenoson, 0.1 mg496124
Ultrasound of both sides of head and neck blood flow334328

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 23 payments worth $566 in total to this clinician.

By company
Novartis Pharmaceuticals Corporation$234
Kestra Medical Technology Services, Inc.$57.51
Amgen Inc.$54.98
Philips North America LLC$44.79
Boehringer Ingelheim Pharmaceuticals, Inc.$36.07
E.r. Squibb & Sons, L.l.c.$31.15
Merck Sharp & Dohme LLC$30.96
Cleerly, Inc.$24.75
By type
Food and Beverage$566

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Louisiana →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $26,382 in research payments for these studies, mostly to the institutions running them.

  • Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
    Novartis Pharmaceuticals Corporation
  • A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
    Novartis Pharmaceuticals Corporation
  • A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in Lafayette

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 19, 2009), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1861682239. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.